Año 2023 / Volumen 115 / Número 10
Original
Fecal immunochemical test for hemoglobin versus fecal calprotectin to monitor endoscopic activity in inflammatory bowel disease

553-558

DOI: 10.17235/reed.2023.9536/2023

Patricia Latorre Añó, Jorge Torrente Sánchez, Amparo Almudena Pérez Ibañez, Jose María Tenias Burillo, Nadia Paloma Moreno Sánchez, Antonio López-Serrano, Eduardo Moreno Osset, Julián Murado Pardo, José María Paredes,

Resumen
Aim: endoscopy identifies inflammatory activity, however, it is an unpleasant test and is not always accessible. The aim of the study was to compare the usefulness of quantitative fecal immunochemical test (FIT) versus fecal calprotectin (FC) to determine endoscopic activity in patients with inflammatory bowel disease (IBD). Methods: cross-sectional prospective observational study. The stool samples were collected within three days before starting the preparation for the colonoscopy. We used the Mayo index for ulcerative colitis (UC) and the simplified endoscopic index for Crohn’s disease (CD). Mucosal healing (MH) was defined as the score 0 points in each of the endoscopic indices. Results: eighty-four patients were included, 40 (47.6 %) with UC. In patients with IBD, FIT and FC showed a significant correlation with the presence of inflammatory activity/MH on endoscopy, with no statistically significant differences between the two receiver-operating characteristic (ROC) curves. Both tests improved their diagnostic performance when assessing patients with UC; the Spearman correlations between FIT and FC and endoscopic inflammatory activity were r = 0.6 (p = 0.0001) and r = 0.7 (p = 0.0001), respectively. In Crohn’s disease, the diagnostic utility of both tests was lower. Conclusions: FIT is an alternative to monitor endoscopic activity among ulcerative colitis patients. In Crohn’s disease, more studies are needed to determine the role of fecal biomarkers.
Resumen coloquial
Estudio observacional prospectivo que tiene como objetivo comparar la utilidad del test de sangre oculta en heces inmunoquímico (TSOH-i) vs la calprotectina fecal (CF) para determinar la actividad endoscópica en pacientes con enfermedad inflamatoria intestinal (EII). En pacientes con EII, ambos biomarcadores fecales muestran una correlación significativa con la presencia de actividad inflamatoria/curación mucosa, sin diferencias estadísticamente significativas. El rendimiento diagnóstico mejora cuando se valoran los pacientes con colitis ulcerosa (CU) y empeora en la enfermedad de Crohn (EC). Se concluye que el TSOH-I es una alternativa a la CF para monitorizar la actividad endoscópica en pacientes con CU.
Share Button
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Bibliografía
1. Gonczi L, Bessissow T, Lakatos PL. Disease monitoring strategies in inflammatory bowel diseases: what do we mean by “tight control”?. World J Gastroenterol. 2019;25:6172-6189.
2. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160:1570-1583.
3. D’Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218-2224.
4. Zhulina Y, Cao Y, Amcoff K, et al. The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease. Aliment Pharmacol Ther. 2016;44:495-504.
5. Kato J, Hiraoka S, Nakarai A, et al. Fecal immunochemical test as a biomarker for inflammatory bowel disease: can it rival fecal calprotectin?. Intest Res. 2016;14:5-14.
6. Hiraoka S, Kato J, Nakarai A, et al. Consecutive measurements by faecal immunochemical test in quiescent ulcerative colitis patients can detect clinic relapse. J Crohn Colitis. 2016;10:687-694.
7. Ryu DG, Kim HW, Park SB, et al. Assessment of disease activity by faecal immunochemical test in ulcerative colitis. World J Gastroenterol. 2016;28:10617-10624.
8. Vilkin A, Rozen P, Levi Z, et al. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol. 2005;100:2519–2525.
9. Takashima S, Kato J, Hiraoka S, et al. Evaluation of mucosal healing in ulcerative colitis by fecal calprotectin vs. fecal immunochemical test. Am J Gastroenterol. 2015;110:873-880.
10. Inokuchi T, Kato J, Hiraoka S, et al. Fecal immunochemical test versus fecal calprotectin for prediction of mucosal healing in Crohn´s disease. Inflamm Bowel Dis. 2016;22:1078-1085.
11. Kuriyama M, Kato J, Takemoto K, et al. Prediction of flare-ups of ulcerative colitis using quantitative immunochemical fecal occult blood test. World J Gastroenterol. 2010;16:1110-1114.
12. Dai C, Jiang M, Sun MJ, et al. Fecal immunochemical test for predicting mucosal healing in ulcerative colitis patients: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2018;33:990–7.
13. Mooiweer E, Fidder HH, Siersema PD, et al. Fecal hemoglobin and calprotectin are equally effective in identifying patients with inflammatory bowel disease with active endoscopic inflammation. Inflamm Bowel Dis. 2014;20:307-14.
14. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–1629.
15. Daperno M, D’Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004;60:505–512.
16. Fraser CG, Allison JE, Halloran SP, et al; Expert Working Group on Fecal Immunochemical Tests for Hemoglobin, Colorectal Cancer Screening Committee, World Endoscopy Organization. A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin. J Natl Cancer Inst. 2012;104:810-814.
17. Reenaers C, Bossuyt P, Hindryckx P, et al. Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice. United European Gastroenterol J. 2018;6:1117- 1125.
18. Simon EG, Wardle R, Thi AA, et al. Does fecal calprotectin equally and accurately measure disease activity in small bowel and large bowel Crohn’s disease? A systematic review. Intest Res. 2019;17:160-170.
19. Sipponen T, Savilahti E, Kolho KL, et al. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008;14:40-46.
20. Gecse KB, Brandse JF, van Wilpe S, et al. Impact of disease location on fecal calprotectin levels in Crohn’s disease. Scand J Gastroenterol. 2015;50:841-847.
Artículos relacionados

Carta

Linfoma T hepatoesplénico y enfermedad inflamatoria intestinal

DOI: 10.17235/reed.2023.9472/2023

Carta

Apoptotic colopathy as a manifestation of Good’s syndrome

DOI: 10.17235/reed.2021.8297/2021

Original

Radon exposure and inflammatory bowel disease in a radon prone area

DOI: 10.17235/reed.2021.8239/2021

Revisión

Enfermedad inflamatoria intestinal y trasplante de órganos sólido

DOI: 10.17235/reed.2020.7361/2020

Editorial

Diet in the etiology of inflammatory bowel disease

DOI: 10.17235/reed.2018.6119/2018

Caso Clínico

Lesiones serradas en pacientes con enfermedad inflamatoria intestinal

DOI: 10.17235/reed.2019.5910/2018

Editorial

Redes sociales online y enfermedad inflamatoria intestinal

DOI: 10.17235/reed.2018.5496/2018

Carta al Editor

Hipertensión portal idiopática por tiopurinas

DOI: 10.17235/reed.2018.5256/2017

Instrucciones para citar
Latorre Añó P, Torrente Sánchez J, Pérez Ibañez A, Tenias Burillo J, Moreno Sánchez N, López-Serrano A, et all. Fecal immunochemical test for hemoglobin versus fecal calprotectin to monitor endoscopic activity in inflammatory bowel disease. 9536/2023


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 826 veces.
Este artículo ha sido descargado 103 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 16/02/2023

Aceptado: 19/04/2023

Prepublicado: 28/04/2023

Publicado: 09/10/2023

Tiempo de revisión del artículo: 54 días

Tiempo de prepublicación: 71 días

Tiempo de edición del artículo: 235 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas